The PR will make new beginnings. He does not say "filings". To me that says possibility of a buyout or a merger, maybe uplist to NASDAQ? However with buyout or merger we would not necessarily have to file. A PR would certainly suffice to explain a buyout or merger. Buyout valuation would be the value of all the companies rolled up plus the value of medications both OTC and prescription that are in pipeline and/or approved. Clinically proven is a very valuable commodity and we have it imo!